Acquisition of the Company by Biolab

In a move to broaden its international reach, Biolab Pharma ventured into the global market by acquiring Exzell Pharma in 2022. With a solid 26-year track record in the pharmaceutical industry, Biolab has established a strong presence across several healthcare sectors in Brazil, including gynecology, gastroenterology, central nervous system, and pediatrics, and is a frontrunner in cardiology and dermatology. This strategic acquisition allows Biolab and Exzell to combine their expertise and extensive product portfolios, ensuring that the Canadian market receives the same exceptional quality that has been synonymous with their work beyond borders.